

[illegible]

<400> Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr
5 10

<210> SEQ ID NO: 3

<211> 12

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Deduced as complementary to TGF β 1, position 731-742

<400> Thr Ser Leu Asp Ala Thr Met Ile Trp Thr Met Met
 5 10

<210> SEQ ID NO: 4

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Overlapping with the extracellular region of the rat type III receptor,
position 245-259

<400> Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Ile Val Asp Ile
 5 10 15

<210> SEQ ID NO: 5

<211> 9

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Modification P54 deduced as complementary to TGF β 1, position 731-742

<400> Thr Ser Leu Met Ile Trp Thr Met Met
 5

<210> SEQ ID NO: 6

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from the modified human type III receptor, position 729-742

<400> Thr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met Met Gln Asn
5 10

<210> SEQ ID NO: 7

<211> 14

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Derived from the modified human type III receptor, position 241-254

<400> Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Thr Ile Asp
5 10

<210> SEQ ID NO: 8

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Position 247-261 of endoglin

<400> Glu Ala Val Leu Ile Leu Gln Gly Pro Pro Tyr Val Ser Trp Leu
5 10 15

<210> SEQ ID NO: 9

<211> 15

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Position 445-459 of endoglin

<400> Leu Asp Ser Leu Ser Phe Gln Leu Gly Leu Tyr Leu Ser Pro His
5 10 15

<210> SEQ ID NO: 10

<211> 23

<212> Peptide

<213> Artificial sequence

<220> Domain

<223> Modification P12, position 322-335 of TGFβb1

<400> His Glu Pro Lys Gly Tyr His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr
5 10 15
Ile Trp Ser Leu Asp Thr
20